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Abstract OBJECTIVE: Silver-Russell Syndrome is both clinically and genetically a het-
erogeneous syndrome. Among the most important dysmorphic features of this 
condition are: a triangular shaped face with a small mandible, a prominent frontal 
eminence, a thin vermilion border with downward-pointing lip corners, clino- and 
brachydactyly of the 5th fingers as well as body asymmetry. The most well-known 
genetic mutations in this syndrome are: the 11p15 epimutation (20–60% patients) 
and the maternal uniparental chromosome 7 disomy present in 7% to 15% of 
patients. Children with SRS have severely impaired physical growth – intrauterine 
and after birth. This, together with the aforementioned dysmorphic features, 
forms the main diagnostic criteria. 
MATERIAL AND METHODS: The study group consisted of 12 children treated with 
growth hormone, aged 2 to 17 (8.9±4.0 years), therein, all of whom met the phe-
notype diagnostic criteria by Wollmann and Price. The effects of growth hormone 
therapy on somatic development of these children are also presented. 
RESULTS: Height and weight improved as a result of growth hormone treatment, 
but the effects were significantly worse than in children with IUGR. Children from 
the study group presented also a smaller an improvement in growth velocity than 
children from the control group, but the difference was statistically insignificant. 
CONCLUSIONS: Growth hormone therapy accelerates the growth of children with 
SRS but to a smaller extent than the growth of children born with intrauterine 
growth retardation without dysmorphic features.
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INTRODUCTION
Silver-Russell Syndrome is both clinically and geneti-
cally a heterogeneous syndrome. It presents a wide 
spectrum of clinical signs with a diverse manifestation 
of dysmorphic features, such as a triangular shaped face 
with a small mandible, a prominent frontal eminence, 
relative macrocephaly, ear lobe structure disorders, a 
thin vermilion zone with a long philtrum, downward-
pointing lip corners and body asymmetry (Wollmann et 
al. 1995; Price et al. 1999). The most well-known genetic 
mutations in this syndrome are: the 11p15 epimutation 
found in 20% to 60% patients and the maternal unipa-
rental chromosome 7 disomy (7–15%) (Netchine et al. 
2007; Bruce et al. 2009; Bartholdi et al. 2009; Schönherr 
et al. 2006; Kotzot et al. 2008).
Silver-Russell Syndrome is related to an intrauter-
ine growth retardation with a postnatal height deficit. 
Neonates with SRS are born on time and their birth 
weight is often below –2 SD. Later these children pres-
ent with dwarfism and normal body proportions. Low, 
but consistent growth rate without catch-up growth 
constitutes to an intensification of growth retardation 
(Binder et al. 2011; Wakeling et al. 2011). Height deficit 
is amid the most serious impairments in children with 
SRS (Toumba et al. 2010). Such children do not reach 
their genetic growth potential and they are significantly 
shorter in adulthood (Cutfield et al. 2007). Contrary to 
most children born with IUGR, patients with SRS do 
not experience catch-up growth (Wollmann et al. 1995, 
Mascarenhas et al. 2012). Their growth rate is very low in 
postnatal and early childhood age (Cutfield et al. 2007).
As children with SRS have a negative growth prog-
nosis, Tanner and Ham (Tanner et al. 1969) proposed 
early growth hormone treatment of these children. 
According to commonly accepted guidelines, short chil-
dren born with intrauterine growth retardation should 
begin growth hormone therapy after reaching the age 
of 4 (Wakeling et al. 2011). Growth hormone treatment 
introduced during puberty improves final height, but is 
less effective than when started in childhood. Growth 
hormone therapy, when introduced in childhood, led 
to a normalization of final height – height standard 
deviation within the normal range and higher by 
2.1SD compared to the height of children, who began 
the treatment in puberty (Cutfield et al. 2007). Most 
authors underline the high importance of the dosage 
prescribed. A correlation was shown between the dose 
and the growth rate, especially in the first year of treat-
ment (Ranke et al. 2003; Boguszewski et al. 1998; Sas 
et al. 1999). It was concluded that 85% short kids born 
with intrauterine growth retardation achieve height 
within the population norms after 7–8 years of high 
dose growth hormone therapy (Cutfield et al. 2007). 
The data regarding long-term growth hormone 
treatment of children with SRS are scarce. In a group 
of 33 children with SRS, a low dose of this medication 
led to an improvement in height by 1.8 SD (Cutfield 
et al. 2007; Azcona et al. 1999). Growth rate improve-
ment of children with SRS is at least comparable to the 
growth rate of other children with IUGR treated with 
GH (Cutfield et al. 2007). However, despite growth 
hormone treatment, patients with SRS do not achieve 
normal adult height, even though their final height 
is far greater than the height of people not receiving 
such therapy (Azcona et al. 1999; Azcona et al. 1998). 
Newest study conducted by Toumba et al. in 2010 with 
26 children with SRS treated with growth hormone for 
a longer period of time (average 9.8 years) showed a 
substantial improvement of height with a final height 
within population norms (–1.3 SD). Higher increase 
in height was observed in patients with lower height at 
the beginning of therapy (Wakeling et al. 2011; Mascar-
enhas et al. 2012).
Based on a number of studies, a high occurrence 
of growth hormone deficit (13–67%) was observed in 
short children with intrauterine growth retardation 
(De Zegher et al. 2000; De Zegher et al. 2005; Ong et 
al. 2005; De Zegher et al. 2002; Stanhope et al. 1989; 
Boguszewski et al. 1995). In children with SRS such a 
deficit is less frequent – 2%. It may point at a smaller 
biological activity of growth hormone in children with 
SRS or at a partial peripheral resistance to its effects 
(Lewandowska et al. 2002; Rakover et al. 1996).
Particularly underlined is the fact of beneficial 
effects of large doses of growth hormone on catch-up 
growth (De Zegher et al. 2000; Chatelain et al. 1993; 
Czernichow et al. 1997; Hokken-Koelega et al. 1999; De 
Zegher et al. 1999), as it is highly unlikely for children 
with SRS to achieve such a type of growth on their own 
(Toumba et al. 2010).
Earlier studies suggested that interrupting high 
dosage growth hormone therapy after two years in 
children with SRS in prepubertal age does not result in 
a deceleration of growth rate (Azcona et al. 1999; De 
Zegher et al. 1997). It may show that these children do 
not have to be treated until final height is reached, con-
trary to other short children with intrauterine growth 
retardation (Binder et al. 2011). Although there is not 
enough data on final effects of growth hormone therapy 
in children with SRS, it appears to be sensible and safe 
(Stanhope et al. 1991).
Study goal
The effect of growth hormone therapy on somatic 
development of group of Polish children with Silver 
Russell Syndrome.
MATERIAL AND METHODS:
The study included 12 children at the age of 2 to 17 
years (x – 8.9±4.0 years) diagnosed with Silver-Russell 
syndrome based on phenotype features. To the study 
qualified were children who fulfilled the diagnostic cri-
teria of SRS by Wollmann et al. (1995) and by Prince et 
al. (1999).
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All the children were under care of Department of 
Pediatrics, Endocrinology, Diabetology, Metabolic Dis-
eases and Cardiology of Developmental Age, Pomera-
nian Medical University in Szczecin or other centres in 
Poland (30 children from Szczecin, 3 from Warsaw and 
5 from Cracow).
Children were treated with growth hormone due to 
somatotroph pituitary insufficiency or short stature as 
a result of intrauterine growth retardation.
Each child was height and weight measured. The 
results were input on percentile population nets of 
Polish children by I. Palczewska and Z. Niedźwiecka 
(2001), considering age and gender. Standard devia-
tions (SD) of height and weight were also calculated.
The control group consisted of 16 children treated 
with growth hormone in a standard dose, at the age of 
2 to 17 years (x – 9.6±3.9 years), chosen randomly to 
match age and gender of children from the study group. 
These children were born with intrauterine growth 
retardation, that is a birth weight ≤–2 SD in relation to 
their gender and gestational age and without any dys-
morphic features. They also have an afterbirth growth 
impairment, i.e. height ≤–2SD for their age and gender. 
An analysis of somatic development was performed in 
the control group, the same as in the study group. The 
control group was a comparison reference point to the 
study group in terms of somatic development.
RESULTS 
In a studied group 12 children with Silver-Russell 
syndrome diagnosed using phenotype criteria, were 
treated with growth hormone. Three children began 
their therapy at the age of 6, four at the age of 7, one at 
the age of 8, one at the age of 10, two at the age of 11 and 
one at the age of 15. One child had begun the therapy 
at advanced bone age, therefore, the treatment period 
was shorter than one year. In one child the therapy was 
maintained for one year, in 2 children – 2,3 and 4 years 
and in one child – 5, 8, 9 and 10 years. Out of 12 chil-
dren, 8 were treated for over 2 years.
In the control group 16 children received growth 
hormone. The therapy was introduced to 3 children at 
the age of 6, to 2 children at the age of 7, to one child at 
the age of 8, to three children and the age of 9, to two 
children at the age of 10, to one at the age of 11, 12 and 
13. In the control group one child was treated for less 
than a year. In one the therapy was sustained for one 
year, two children were treated for 2 years, 2 children 
for 7 years, 3 children for 3 years, 3 children for 6 years 
and 4 children for 5 years. Out of 16 children treated 
with growth hormone, 12 were treated for over 2 years.
Figure 1 shows the effect of growth hormone treat-
ment on the height of these children.
At the beginning of growth hormone therapy chil-
dren from the study group had a larger height deficit 
expressed in SD compared to these children, who did 
not receive such treatment. During therapy a significant 
(p<0.05) improvement in height deficit (height SD) was 
seen from the age of 6 to 11. At the age of 17 only one 
patient from the study group continued growth hor-
mone therapy. Therefore, despite seeing a significant 
difference of height expressed in standard deviation 
of 1.3SD between the treated child and the untreated 
children, the statistical significance of this difference 
was not calculated on account of the small number of 
children with this age.
Children from the control group treated with growth 
hormone at ages 6 to 8 and 11 to 17 were significantly 
(p<0.05) higher (height expressed in SD) than these, 
who did not receive such therapy, however, at ages 9 
and 10 these differences were not significant.
Treatment
no
yes
Study group 
6 7 8 9 10 11 12 13 14 15 16 17
Age [years]
5
4
3
2
1
0
H
ei
gh
t S
D
Control group 
6 7 8 9 10 11 12 13 14 15 16 17
p<0.05
p=0.05
p=0.05
Fig. 1. Height SD of children treated with growth hormone from the study and the control groups (mean values).
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At the end of observation period, no significant 
differences were observed between children from the 
study and control groups in reference to age and time 
of therapy. Mean therapy time (assuming only the chil-
dren treated over 2 years) was, both in the study and the 
control group, slightly over 5 years.
Figure 2 compared the height SD of children from 
the study and the control group before introducing 
growth hormone treatment, after one and two years of 
therapy at the last year of observation.
Significantly larger growth deficit in height SD was 
spotted in subsequent years of GH therapy in children 
from the study group, compared to the control group. 
It is important to note, however, that the children from 
the study group began the therapy with significantly 
(p<0.003) smaller height than children from the con-
trol group. Growth hormone treatment significantly 
improved the height SD of children from the study 
group during the first and second years of therapy. In 
the following years no such improvement was seen.
Figure 3 compares the growth rate before beginning 
growth hormone therapy, one and two years after intro-
ducing such therapy and at the last year of observation.
As seen on Figure 3. children from both the control 
and the study group had similar height gains before 
beginning and during growth hormone therapy. How-
ever, during all years of therapy the growth rate of chil-
dren from the study group was slightly slower than in 
the control group.
Figure 4 shows growth rate SD before introducing 
growth hormone treatment, one year and two years 
after introducing such treatment and at the last year of 
observation.
As seen on Figure 4 no significant difference was 
seen in growth rate SD between children from the study 
and the control group treated with growth hormone, 
both before, as during the first and second year of intro-
ducing such therapy, although a statistically significant 
(p=0.015) lower growth rate SD was seen in children 
from the study group above 2 years from beginning 
growth hormone therapy.
Figure 5 compares weight SD of children from the 
study and the control groups before beginning growth 
hormone treatment, one and two years after introduc-
ing such therapy and at the last year of observation.
Children from the study group began the treatment 
with significantly lower weight compared to the control 
group. However, under growth hormone therapy, the 
weight SD improved mainly in the study group, there-
fore at the last year of observation the weight SD differ-
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Fig. 2. Height SD of children from the study and the control group 
in subsequent years of growth hormone therapy (mean values 
with 95% confidence intervals).
Fig. 3. Growth rate of children from the study and the control group 
in subsequent years of growth hormone therapy (mean values 
with 95% confidence intervals).
Fig. 4. Growth rate SD of children from the study and the control 
group in subsequent years of growth hormone therapy (mean 
values with 95% confidence intervals).
Fig. 5. Weight SD of children from the study and the control group 
in subsequent years of growth hormone therapy (mean values 
with 95% confidence intervals).
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ence between children from the study and the control 
group decreased.
2 children with the genetic change (1 child with 
maternal uniparental disomy of chromosome 7 and 
11p15 epimutation and 1 child with epimutation 11p15) 
were treated with recombinant human growth hormone.
The boy with maternal uniparental disomy of chro-
mosome 7 began growth hormone therapy at the age of 
10. After introducing recombinant human growth hor-
mone treatment his growth rate improved noticeably, 
especially during the first year of therapy. His height SD 
before beginning therapy was only –3.75 and after two 
years of observation –2.02.
The girl with the 11p15 epimutation began treat-
ment at the age of 8.
After one year of recombinant human growth hor-
mone therapy her growth rate slightly improved. Before 
beginning therapy this child’s height SD was –3.84 and 
after one year of treatment –3.46.
A comparison of growth parameters of two children 
with a genetic change (maternal uniparental disomy of 
chromosome 7 and 11p15 epimutation) after one year 
of growth hormone therapy showed that the boy with 
mUPD7 had a notably better response to treatment. His 
growth rate after one year of rhGH therapy improved 
from 5.9 cm/year to 13.5 cm/year, while the girl with 
11p15 epimutation improved her growth rate from 
5.2 cm/year to only 6.3 cm/year. 
DISCUSSION
Growth hormone therapy has a positive effect on chil-
dren with intrauterine growth retardation, including 
children with SRS (Rakover et al. 1996; Chatelain et 
al. 1993; Christofordis et al. 2005; Ranke et al. 1996; 
Chernausek et al. 1996; Stanhope et al. 1991). Several 
studies confirm beneficial effects of treating children 
with SRS (Lewandowska et al. 2002; Rakover et al. 1996; 
Christofordis et al. 2005; Ranke et al. 1996; Chernausek 
et al. 1996). It appears that early introduction of growth 
hormone therapy should positively affect growth and 
improve the quality of life of these patients. Introducing 
growth hormone therapy in later age also results in an 
improvement of height, although not as high, as if the 
treatment was begun in the prepubertal period (Cut-
field et al. 2007; Mascarenhas et al. 2012).
Since 2015 growth hormone therapy for SRS 
patients in Poland is financed by the National Health 
Fund (NFZ), as part of short stature treatment for SGA 
children. Our observation is, however, a first descrip-
tion of treatment effects in 12 patients from before the 
treatment was refunded. Therefore, out of 38 children 
with phenotype features of SRS, only 12 were treated 
with growth hormone on the basis of somatotroph 
pituitary insufficiency or intrauterine growth retarda-
tion. Therapy introduction was also largely limited by 
the advanced age of patients at diagnosis. Thus, the 
age of patients at the beginning of therapy differed. 
Two youngest children were 6 years old and the oldest 
one – 15 years old. Numerous children did not receive 
growth hormone because of their age at the time of 
diagnosis. The observation of the effects of therapy was 
too short, since most patients did not complete their 
therapy. Growth hormone did not only increase height 
– from –4.02 SD to –2.99 SD, i.e. 1 SD, during the last 
year of observation, but also weight – from –3.56 SD 
to –2.36 SD. Height and weight gains were significantly 
bigger in a group of children with SRS, compared to the 
group with intrauterine growth retardation. Although 
at the end of the observation period higher weight and 
height was achieved by children with IUGR. It is, how-
ever, important to note, that children with SRS began 
the treatment with a substantially larger higher and 
weight deficit, much like the group observed by Ranke 
et al. in 2010. In our study, as in the study by Ranke 
et al. (2010), this difference was approximately 1 SD. 
The growth rate during the first two years of treatment 
was comparable between children with SRS and chil-
dren with UIGR, albeit in the last year of observation, 
a significantly faster growth rate was seen in children 
with IUGR. It means, that children with SRS grow best 
during the first two years of therapy, unlike children 
with IUGR, who achieve good height gains also in later 
years of treatment. This result confirms the observation 
of other researchers (Cutfield et al. 2007).
Growth hormone therapy has a lot of positive effects 
on children with SRS. It leads not only to faster vertical 
growth, but is also beneficial for muscle mass growth, 
bone mineralization, and improves the quality of life 
and perception skills of these children (Cutfield et al. 
2007). Despite the possible side effects, the advantages of 
growth hormone therapy outweigh the harmful effects.
During an approximately ten-year observation, 
Toumba et al. (2010) analysed the growth of 26 children 
with Silver-Russell Syndrome treated with growth hor-
mone. The cited author reached similar conclusions, 
pointing at a positive effect of growth hormone therapy 
in that study. Median height at the beginning of ther-
apy was –2.7 SD and it increased to –1.3 SD during the 
therapy. The control group consisting of children with 
IUGR reached a final height of approximately –1.0. 
Despite a noticeable final height improvement, no child 
reached the desired final height. In the group examined 
by this author the biggest height gains were observed at 
the beginning of puberty (Toumba et al. 2010).
It was commonly believed that pubertal growth spurt 
in children with SRS occurs a lot earlier than in normal 
population (Tanner et al. 1975). Toumba et al. (2010) 
observed, that growth hormone therapy may lead to 
a large growth rate acceleration, if introduced before 
puberty. This author states, however, that this data is 
not entirely reliable due to a small number of treated 
patients and a varied age of children at therapy intro-
duction. Similar results were described earlier, although 
then, the observation period was shorter (Rakover et al. 
1996; Chatelain et al. 1993; Ranke et al. 1996). Ranke et al. 
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(1996) suggests that despite discontinuing growth hor-
mone therapy, children with SRS sustain good growth 
rate and perhaps, contrary to children with IUGR, a 
continuation of treatment until achieving final height 
would be, in case of children with SRS, unnecessary.
The views on growth hormone dosage vary. In 
the above studies, children were treated with 0.16–
0.43 mg/kg/week. (average 0.25 mg/kg/week.).
It is commonly approved, that it is crucial to intro-
duce treatment in an early period of life, to “maximize” 
the growth promoting effect. Some authors believe that 
to achieve the desired effect a much larger dose should 
be used than in the treatment of somatotroph pituitary 
insufficiency (Chatelain et al. 1993; Albanese et al. 1997; 
Chatelain et al. 1994). Other studies suggest, however, 
that despite applying different doses to all treated 
children, a significant growth rate acceleration was 
achieved (De Zegher et al. 2000; Chatelain et al. 1993; 
De Zegher et al. 1999).
The effectiveness of treating children with SRS 
with growth hormone is confirmed by data from the 
Australian OZGROW programme. In that study after 
5 years of treatment the height deficit of children with 
SRS decreased from –3.2 SD to –2.0 SD. Increasing the 
dose did not further improve the growth rate of those 
patients, although a better growth response was seen in 
younger and shorter patients (Lewandowska et al. 2002; 
Rakover et al. 1996; Mascarenhas et al. 2012).
Similar data was presented by Ranke et al. in a study 
from 2010, where he describes the effects of growth 
hormone therapy on 161 children with IUGR, includ-
ing 55 with SRS. Despite using a much higher growth 
hormone dose in patients with SRS, this author did not 
achieve significant differences in height gains during 
the first and subsequent years of therapy between chil-
dren with SRS and IUGR.
In the study of Binder et al. (2013) the genotype was 
not a significant predictor of height gain in population 
children with SRS. There was however a trend toward a 
batter outcome in children with mUPD7 (Binder et al. 
2013), but in our study, a comparison of growth param-
eters of two children with a genetic change (maternal 
uniparental disomy of chromosome 7 and 11p15 epi-
mutation) after one year of growth hormone therapy 
showed clearly, that the boy with mUPD7 had a nota-
bly better response to treatment. His growth rate after 
one year of rhGH therapy improved from 5.9 cm/year 
to 13.5 cm/year, while the girl with 11p15 epimutation 
improved her growth rate from 5.2 cm/year to only 
6.3 cm/year. However this observation needs to be con-
firmed in larger cohorts (Binder et al. 2013).
CONCLUSIONS
Recombinant human growth hormone therapy pro-
motes somatic growth in children with Silver-Russell 
Syndrome, although to a smaller degree than in chil-
dren with intrauterine growth retardation.
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